Edition:
United States

Trevena Inc (TRVN.OQ)

TRVN.OQ on NASDAQ Stock Exchange Global Select Market

1.65USD
15 Dec 2017
Change (% chg)

$0.09 (+5.77%)
Prev Close
$1.56
Open
$1.56
Day's High
$1.65
Day's Low
$1.55
Volume
1,223,645
Avg. Vol
157,661
52-wk High
$8.00
52-wk Low
$1.35

Latest Key Developments (Source: Significant Developments)

Trevena Inc says Q3 loss per share $0.27
Tuesday, 7 Nov 2017 07:00am EST 

Nov 7 (Reuters) - Trevena Inc -:Trevena reports third quarter 2017 financial results and announces new positive clinical trial data.Q3 loss per share $0.27.Q3 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S.Trevena Inc - ‍expects to be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months​.  Full Article

Trevena announces submission of NDA to U.S. FDA for Olinvo
Thursday, 2 Nov 2017 07:00am EDT 

Nov 2 (Reuters) - Trevena Inc :Trevena announces submission of new drug application to U.S. FDA for Olinvo (oliceridine injection).Trevena Inc - "‍look forward to working with FDA during review process and to a potential NDA approval of Olinvo in 2018"​.  Full Article

Trevena announces restructuring to focus resources on commercial strategy
Wednesday, 11 Oct 2017 04:01pm EDT 

Oct 11 (Reuters) - Trevena Inc :Trevena announces restructuring to focus resources on commercial strategy.Trevena Inc - ‍new drug application for olinvo remains on track​.‍New Drug Application for Olinvo remains on track for submission in October​.Trevena Inc - ‍company is reducing its workforce by approximately 30 percent, or 21 full time employees​.Trevena Inc - ‍company continues to expect to report data later this year from ongoing phase 1 study of TRV250​.Trevena Inc - ‍also expects to incur a charge in Q4 of 2017 of approximately $2.0 million related to reduction ​.Trevena inc - ‍company expects to report cash, cash equivalents and marketable securities as of September 30, 2017 of approximately $76.7 million​.Trevena-Intends to complete ongoing Phase 1 trial of TRV250 for acute migraine, will also assess options for further development of asset.Trevena - ‍estimates workforce reduction, other initiatives, will reduce cash expected to be used in activities over next 3 calendar years by about $40 million​.Trevena Inc - ‍company expects cash, cash equivalents and marketable securities will be sufficient to support operations into Q4 of 2018.Trevena INC - ‍intends to complete ongoing Phase 1 trial of TRV250 for acute migraine​.  Full Article

Trevena Q2 loss per share $0.35
Thursday, 3 Aug 2017 07:00am EDT 

Aug 3 (Reuters) - Trevena Inc ::Trevena reports second quarter 2017 financial results and provides corporate update.Q2 loss per share $0.35.Q2 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S.Trevena Inc says olinvo program on track for NDA submission in September/October 2017.  Full Article

Trevena Q1 loss per share $0.36
Thursday, 4 May 2017 07:00am EDT 

May 4 (Reuters) - Trevena Inc :Trevena reports first quarter 2017 financial results and provides corporate update.Q1 loss per share $0.36.Q1 earnings per share view $-0.53 -- Thomson Reuters I/B/E/S.  Full Article

Trevena reports presentation of positive results from two phase 3 pivotal efficacy studies of olinvo
Thursday, 6 Apr 2017 07:00am EDT 

Trevena Inc : Trevena-Announced presentation of positive results from two phase 3 pivotal efficacy studies of olinvo . Trevena Inc - data showed significant efficacy of olinvo in managing moderate-to-severe acute pain . Trevena - data included head-to-head comparisons to iv morphine suggesting olinvo could be new analgesic option for patients at risk of opioid-related aes . Trevena - "results suggest that olinvo can be dosed to manage moderate-to-severe acute pain, so that patients may titrate opioid dosing as needed" . Trevena Inc - results from studies recapitulate earlier clinical trial results .Trevena Inc - on track to submitting new drug application to FDA for olinvo in Q4 of this year.  Full Article

Trevena posts Q4 loss per share $0.67
Wednesday, 8 Mar 2017 07:00am EST 

Trevena Inc : Trevena reports full year 2016 earnings . Q4 loss per share $0.67 . Q4 earnings per share view $-0.62 -- Thomson Reuters I/B/E/S . Trevena inc - Olinvo program on track for NDA submission in Q4 of 2017 . Trevena Inc- company expects that expenses will decrease in 2017 compared to 2016 .Trevena Inc - cash, cash equivalents, and marketable securities were $110.6 million as of December 31, 2016.  Full Article

Trevena reports positive top-line results from two phase 3 pivotal efficacy studies of intravenous oliceridine
Tuesday, 21 Feb 2017 07:00am EST 

Trevena Inc : Trevena announces positive top-line results from two phase 3 pivotal efficacy studies of intravenous oliceridine in moderate-to-severe acute pain . Trevena inc says in both studies, oliceridine was generally safe and well-tolerated . Trevena inc - program is on track for nda submission in 4q 2017 . Trevena inc says oliceridine program is on track for nda submission in 4q 2017 .Trevena -additional clinical, non-clinical, manufacturing activities remain on track to support nda submission in q4 of this year for oliceridine program.  Full Article

Trevena Q2 loss per share $0.37
Thursday, 4 Aug 2016 07:35am EDT 

Trevena Inc : Q2 loss per share $0.37 . Q2 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S . Trevena reports second quarter 2016 financial results and provides corporate update Further company coverage: [TRVN.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Trevena says TRV027 did not achieve primary or secondary endpoints in BLAST-AHF Phase 2B trial in acute heart failure
Monday, 16 May 2016 07:00am EDT 

Trevena Inc : Expects to focus its efforts on its lead Phase 3 oliceridine pain program and its earlier stage programs .Reports TRV027 did not achieve primary or secondary endpoints in BLAST-AHF Phase 2B trial in acute heart failure.  Full Article

BRIEF-Trevena Inc says Q3 loss per share $0.27

* Trevena reports third quarter 2017 financial results and announces new positive clinical trial data